Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~• Diagnosed with Low High Density Lipoprotein Cholesterol (HDL-C) or hypercholesterolemia, after diet lead-in/washout of lipid therapies~Exclusion Criteria:~* History of coronary heart disease, or hardening of the arteries, or heart does not pump sufficiently well~* Hypertension or high blood pressure that is not under control or your study physician does not consider the electrical activity of heart (Electrocardiogram \[ECG\]) to be compatible with participation in the study~* History of a bad skin rash, a prior rash due to a drug or a history of chronic skin disorder (such as psoriasis or eczema)~* Intolerance to certain lipid modifying drugs (including statins and Cholesteryl Ester Transfer Protein (CETP) inhibitors)~* Not willing to stop taking prescription or over the counter drugs you use to control fats in your blood (like fish oil, niacin or statin) or pills to decrease your weight, including herbs~* Not willing to follow the diet (low-fat) that the study physician will recommend~* Have disease of liver, kidneys, muscles or other organs of body, a serious infection or cancer, or abnormal laboratory tests that study physician does not consider compatible with participation in the study~* Breastfeeding woman or a woman who can still become pregnant, but are not willing to use a valid birth control measure to prevent pregnancies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 30 milligram (mg) LY2484595 monotherapy (Type: EXPERIMENTAL): None
- 100 mg LY2484595 monotherapy (Type: EXPERIMENTAL): None
- 500 mg LY2484595 monotherapy (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- 20 mg Atorvastatin monotherapy (Type: ACTIVE_COMPARATOR): None
- 100 mg LY2484595 + 20 mg Atorvastatin (Type: EXPERIMENTAL): None
- 40 mg Simvastatin monotherapy (Type: ACTIVE_COMPARATOR): None
- 100 mg LY2484595 + 40 mg Simvastatin (Type: EXPERIMENTAL): None
- 10 mg Rosuvastatin monotherapy (Type: ACTIVE_COMPARATOR): None
- 100 mg LY2484595 + 10 mg Rosuvastatin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).